PREDiCT: Autoimmune Disease Modeling Summit
Deploy Advanced Models to Enhance Your Confidence & Und
Deploy Advanced Models to Enhance Your Confidence & Und
Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.